Literatur
-
1
Hawkins B S, Bressler N M, Bressler S B. et al .
Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9.
Arch Ophthalmol.
2004;
122
1597-1611
-
2
Hawkins B S, Miskala P H, Bass E B. et al .
Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: II. Quality-of-life findings from a randomized clinical trial: SST Group H Trial: SST Report No. 10.
Arch Ophthalmol.
2004;
122
1616-1628
-
3
Kirchhof B.
Makulatranslokation. Bessere Prognosen für AMD-Patienten.
Ophthalmologe.
2002;
99
143
-
4
Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.
Retina.
2005;
25
119-134
-
5
Csaky K.
Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls.
Ophthalmology.
2003;
110
879-881
-
6
Folkman J, Merler E, Abernathy C. et al .
Isolation of a tumor factor responsible for angiogenesis.
J Exp Med.
1971;
133
275-288
-
7
Schachat A P.
New treatments for age-related macular degeneration.
Ophthalmology.
2005;
112
531-532
-
8
Ferrara N.
Vascular endothelial growth factor: basic science and clinical progress.
Endocr Rev.
2004;
25
581-611
Prof. Dr. N. Bornfeld
Zentrum für Augenheilkunde, Universitätsklinikum Essen
45122 Essen
Email: retina@uni-essen.de
